Volm M, Mattern J, Koomagi R
Department of Oncological Diagnostics and Therapy, German Cancer Research Center, D-69120 Heidelberg, Germany.
Int J Oncol. 1998 Nov;13(5):975-9. doi: 10.3892/ijo.13.5.975.
The expression of platelet-derived endothelial cell growth factor (PD-ECGF) was determined immunohistochemically in 143 non-small cell lung carcinomas. Staining was observed in 48% of the cases. A relationship between histology, stage, erbB-1, erbB-2, ras and PD-ECGF expression was not found. A relationship of borderline significance was observed between PD-ECGF and p53 expression. There was also no relationship between PD-ECGF expression and proliferative activity (G1 phases, S phases, cyclin A). In contrast, a correlation between PD-ECGF- and VEGF-expression was detectable (p=0.009). Furthermore, PD-ECGF expression was related to the response of lung carcinomas to doxorubicin (p=0.0004). Of 35 sensitive tumors, 26 carcinomas were PD-ECGF-positive (74%) while of 108 resistant carcinomas only 43 tumors (40%) exhibited PD-ECGF expression.
采用免疫组织化学方法检测了143例非小细胞肺癌中血小板衍生内皮细胞生长因子（PD - ECGF）的表达。48%的病例观察到染色。未发现组织学、分期、erbB - 1、erbB - 2、ras与PD - ECGF表达之间存在关联。观察到PD - ECGF与p53表达之间存在临界显著性关系。PD - ECGF表达与增殖活性（G1期、S期、细胞周期蛋白A）之间也无关联。相反，可检测到PD - ECGF与VEGF表达之间存在相关性（p = 0.009）。此外，PD - ECGF表达与肺癌对阿霉素的反应相关（p = 0.0004）。在35例敏感肿瘤中，26例癌组织PD - ECGF呈阳性（74%），而在108例耐药癌组织中，仅有43例肿瘤（40%）表现出PD - ECGF表达。
